For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks ...

Brookfield Asset Management Ltd. walked away from a plan to acquire Grifols SA, ending months of negotiations to take over ...

Brookfield Asset Management Ltd. is preparing to walk away from a plan to acquire Grifols SA over disagreements on valuation.

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the "Clients") holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

Grifols shares fell as much as 14 per cent after the news was published by Bloomberg, the biggest intra-day decline since Feb ...